↓ Skip to main content

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins…

Overview of attention for article published in BMC Cardiovascular Disorders, September 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

blogs
1 blog
patent
19 patents

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
109 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Published in
BMC Cardiovascular Disorders, September 2014
DOI 10.1186/1471-2261-14-121
Pubmed ID
Authors

Helen M Colhoun, Jennifer G Robinson, Michel Farnier, Bertrand Cariou, Dirk Blom, Dean J Kereiakes, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari

Mendeley readers

The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Austria 1 <1%
Mexico 1 <1%
Spain 1 <1%
United States 1 <1%
Unknown 104 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 17%
Student > Master 15 14%
Student > Postgraduate 13 12%
Other 11 10%
Student > Bachelor 10 9%
Other 30 28%
Unknown 12 11%
Readers by discipline Count As %
Medicine and Dentistry 50 46%
Pharmacology, Toxicology and Pharmaceutical Science 14 13%
Agricultural and Biological Sciences 8 7%
Biochemistry, Genetics and Molecular Biology 5 5%
Computer Science 2 2%
Other 13 12%
Unknown 17 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2022.
All research outputs
#2,141,950
of 22,865,319 outputs
Outputs from BMC Cardiovascular Disorders
#72
of 1,613 outputs
Outputs of similar age
#24,892
of 250,797 outputs
Outputs of similar age from BMC Cardiovascular Disorders
#3
of 36 outputs
Altmetric has tracked 22,865,319 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,613 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,797 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.